Anne Polk1, Inge-Marie Svane2, Michael Andersson3, Dorte Nielsen4. 1. Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark. Electronic address: anne.polk@hotmail.com. 2. Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark. Electronic address: inge-marie.svane@regionh.dk. 3. Department of Oncology, Rigshospitalet, University of Copenhagen, Blegdamsvej 9, DK-2100 Copenhagen, Denmark. Electronic address: michael.andersson@regionh.dk. 4. Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Herlev Ringvej 75, DK-2730 Herlev, Denmark. Electronic address: dorte.nielsen.01@regionh.dk.
Abstract
INTRODUCTION: An increasing number of compounds directed against immune checkpoints are currently under clinical development. In this review we summarize current research in breast cancer. MATERIAL AND METHODS: A computer-based literature search was carried out using PubMed and EMBASE; data reported at international meetings and clinicaltrials.gov were included as well. RESULTS: The obtained overall response rate of PD-1/PD-L1 monotherapy varied from 5 to 30% in heavily pretreated triple negative breast cancer (TNBC). The median duration of progression free survival and overall survival were either not reported or short. Still responses were of long duration in a subset of patients. In the neoadjuvant setting, preliminary results including a very limited number of patients suggest high pathological response rates after combined blockade of the PD-1 pathway and chemotherapy. Multiple trials have been initiated to evaluate the combination of other anticancer agents and checkpoint inhibitors, especially in TNBC. In addition, ongoing studies aim to identify biomarkers to guide patient selection. CONCLUSION: Immune checkpoint inhibitors have the potential to produce durable tumor remission and induce long standing anti-tumor immunity in a subgroup of breast cancer patients. However, the identification of predictive biomarkers is crucial for further development of this treatment modality.
INTRODUCTION: An increasing number of compounds directed against immune checkpoints are currently under clinical development. In this review we summarize current research in breast cancer. MATERIAL AND METHODS: A computer-based literature search was carried out using PubMed and EMBASE; data reported at international meetings and clinicaltrials.gov were included as well. RESULTS: The obtained overall response rate of PD-1/PD-L1 monotherapy varied from 5 to 30% in heavily pretreated triple negative breast cancer (TNBC). The median duration of progression free survival and overall survival were either not reported or short. Still responses were of long duration in a subset of patients. In the neoadjuvant setting, preliminary results including a very limited number of patients suggest high pathological response rates after combined blockade of the PD-1 pathway and chemotherapy. Multiple trials have been initiated to evaluate the combination of other anticancer agents and checkpoint inhibitors, especially in TNBC. In addition, ongoing studies aim to identify biomarkers to guide patient selection. CONCLUSION: Immune checkpoint inhibitors have the potential to produce durable tumor remission and induce long standing anti-tumor immunity in a subgroup of breast cancerpatients. However, the identification of predictive biomarkers is crucial for further development of this treatment modality.
Authors: Katie E Hurst; Kiley A Lawrence; Matthew T Essman; Zeke J Walton; Lee R Leddy; Jessica E Thaxton Journal: Cancer Immunol Res Date: 2019-01-18 Impact factor: 11.151
Authors: Aude-Hélène Capietto; Seunghyun Lee; David Clever; Emily Eul; Haley Ellis; Cynthia X Ma; Roberta Faccio Journal: Cancer Immunol Res Date: 2021-09-22 Impact factor: 12.020
Authors: Liqian Ma; Lawrence Wang; Adam T Nelson; Chaeyeon Han; Sisi He; Madeline A Henn; Karan Menon; Joy J Chen; Amy E Baek; Anna Vardanyan; Sayyed Hamed Shahoei; Sunghee Park; David J Shapiro; Som G Nanjappa; Erik R Nelson Journal: Cancer Lett Date: 2020-08-28 Impact factor: 8.679
Authors: Umar Mehraj; Rais A Ganai; Muzafar A Macha; Abid Hamid; Mohammed A Zargar; Ajaz A Bhat; Mohd Wasim Nasser; Mohammad Haris; Surinder K Batra; Bader Alshehri; Raid Saleem Al-Baradie; Manzoor A Mir; Nissar Ahmad Wani Journal: Cell Oncol (Dordr) Date: 2021-09-16 Impact factor: 6.730